title: Inhibitors of the major cysteinyl proteinase (GP57/51) impair host cell invasion and arrest the intracellular development of Trypanosoma cruzi in vitro.
abstract: Peptidyl diazomethane (PDAM) derivatives, a class of irreversible inhibitors for cysteine proteinase, were screened for the ability to impair Trypanosoma cruzi invasion and intracellular development in primary cultures of heart muscle cells (HMC). T. cruzi GP57/51, a purified cysteinyl proteinase, and the substrate Z-Phe-Arg-NHMec were used to determine inhibition rate constants (k'+2) by continuous kinetic assays. The k'+2 values ranged from 25,400 to 2,800. The best inhibitors of GP57/51 had bulky hydrophobic residues in the P1 position (in addition to P2), the S1 sub-site specificity of the enzyme being thus similar to mammalian cathepsin L. The effects of these PDAM on parasite infectivity were then investigated. The ability to invade HMC was markedly impaired when trypomastigotes were briefly exposed to 10 microM of Z-(S-Bzl)Cys-Phe-CHN2. Striking effects were observed when PDAM were added to HMC cultures that had been previously infected with trypomastigotes: Z-(S-Bzl)Cys-Phe-CHN2 with an IC50 of 0.4 microM, and less markedly Z-Phe-Phe-CHN2 and Z-Tyr-Phe-CHN2 (or Z-Phe-Tyr-CHN2) blocked amastigote replication as well as their transformation into trypomastigotes, thereby arresting intracellular development. Bz-Phe-Gly-CHN2, in contrast, failed to display antiparasite activity. Direct characterization of the target cysteinyl proteinase was sought, by incubating viable amastigotes or infected HMC with Z-[125I]Tyr-Phe-CHN2. Affinity labeling implicated GP57/51 as the major cysteinyl proteinase target for this probe. We propose that T. cruzi intracellular development is critically dependent on GP57/51 (cruzipain). Selective inhibitors for this cysteinyl proteinase may have therapeutic potential.
authors.affiliation: Instituto Oswaldo Cruz, Departmento de Ultraestrutura e Biologia Celular, Rio de Janeiro, Brazil.
authors.forename: M N
authors.initials: MN
authors.lastname: Meirelles
authors.forename: L
authors.initials: L
authors.lastname: Juliano
authors.forename: E
authors.initials: E
authors.lastname: Carmona
authors.forename: S G
authors.initials: SG
authors.lastname: Silva
authors.forename: E M
authors.initials: EM
authors.lastname: Costa
authors.forename: A C
authors.initials: AC
authors.lastname: Murta
authors.forename: J
authors.initials: J
authors.lastname: Scharfstein
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000187:drug effects* / Q000378:metabolism; D002478:Cells, Cultured; D003546:Cysteine Endopeptidases / Q000187:drug effects* / Q000378:metabolism; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D006023:Glycoproteins / Q000187:drug effects* / Q000378:metabolism; D015151:Immunoblotting; D007700:Kinetics; D051379:Mice; D015800:Protozoan Proteins; D014349:Trypanosoma cruzi / Q000187:drug effects / Q000201:enzymology* / Q000472:pathogenicity
chemical_list: D000953:Antigens, Protozoan; D015853:Cysteine Proteinase Inhibitors; D006023:Glycoproteins; D015800:Protozoan Proteins; D003546:Cysteine Endopeptidases; C073182:GP57-51 antigen, Trypanosoma cruzi; C063214:cruzipain